Comparative Pharmacology
Head-to-head clinical analysis: SCANLUX 300 versus VARIBAR PUDDING.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SCANLUX 300 versus VARIBAR PUDDING.
SCANLUX-300 vs VARIBAR PUDDING
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SCANLUX-300 (gadoxetate disodium) is a hepatobiliary MRI contrast agent that shortens T1 relaxation time, enhancing signal intensity in tissues. It is taken up by hepatocytes via OATP1B1/1B3 transporters and excreted into bile via MRP2, allowing both dynamic and hepatobiliary phase imaging.
Barium sulfate acts as a radiopaque contrast agent. It has high atomic number (z=56) and density, which attenuates X-rays and provides positive contrast in the gastrointestinal tract. It is not absorbed systemically and coats the mucosal surface, allowing visualization of luminal anatomy and pathology.
30 mg/m² IV over 1 hour every 4 weeks.
125 mL orally once for upper GI studies; 250-500 mL orally once for small bowel follow-through. Not for IV use.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2.8–4.5 h); may be prolonged in hepatic impairment (up to 7 h).
Not applicable; barium sulfate is not absorbed systemically; gastrointestinal transit time is approximately 1–2 hours for gastric emptying and 6–24 hours for colonic passage.
Renal excretion of unchanged drug accounts for approximately 30% of the administered dose; fecal/biliary elimination accounts for about 60% (via hepatobiliary secretion into feces); minimal excretion via other routes.
Varibar (barium sulfate) is not absorbed from the GI tract; it is excreted unchanged in feces. 100% fecal elimination as unabsorbed barium sulfate.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent